Latest Breaking News On - Bluhm family professor of cancer research - Page 1 : comparemela.com

Low-risk DCIS patients may safely skip radiotherapy after surgery, study finds

Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS who received adjuvant radiotherapy, according to results from the E4112 clinical trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.

San antonioUnited statesSeemaa khanFeinberg school of medicineBluhm family professor of cancer researchCancer research groupLurie comprehensive cancer centerCancer research networkAlliance for clinical trials in oncologyNorthwestern universityAmerican association for cancer researchSan antonio breast cancer symposiumBluhm family professorCancer researchFeinberg schoolResearch group

Skipping adjuvant radiotherapy may not impact risk of recurrence or progression in patients with low-risk DCIS

Skipping adjuvant radiotherapy may not impact risk of recurrence or progression in patients with low-risk DCIS
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesSeemaa khanFeinberg school of medicineBluhm family professor of cancer researchNorthwestern universityLurie comprehensive cancer centerCancer research networkCancer research groupAlliance for clinical trials in oncologySan antonio breast cancer symposiumBluhm family professorCancer researchFeinberg schoolClinical trials

Dr Khan on Optimizing Local Therapy Using MRI and a 12-Gene Expression Assay in DCIS

Seema A. Khan, MD, discusses 5-year clinical outcomes from the ECOG-ACRIN E4112 trial, which is evaluating the use of MRI and a 12-gene expression assay to optimize local therapy for patients with ductal carcinoma in situ.

Seemaa khanNorthwestern university feinberg school of medicineBluhm family professor of cancer researchOptimizing local therapy usingGene expression assayPartnership withBluhm family professorCancer researchNorthwestern university feinberg schoolEcog acrin e4112 trialPatients with ductal carcinoma in situ

Multiplicity of agents saturate treatment landscape for de novo metastatic breast cancer

Multiplicity of agents saturate treatment landscape for de novo metastatic breast cancer
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesMindy valcarcelByjennifer southallSeemaa khanSeema khanNorthwestern medicine feinberg school ofBluhm family professor of cancer researchNational comprehensive cancer networkBluhm family professorCancer researchNorthwestern medicine feinberg schoolNorth america

Envisagenics is Awarded Another SBIR Grant From the National Cancer Institute to Commercialize its AI/ML Platform for Immunotherapy Development

/PRNewswire/ Envisagenics, Inc., a New York-based biotechnology company leveraging artificial intelligence (AI) and RNA-splicing analytics for discovery and.

Bradley harrisMartin akermanMaria luisa pinedaNational cancer instituteSmall business innovation researchNational institutes of healthCold spring harbor laboratoryNorthwestern university feinberg school of medicineSusan clare research associate professor of surgeryBluhm family professor of cancer researchPrnewswire envisagenics incSeema khan coNational instituteNew york basedNational institutesChief technology officer